Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;33(4):e5777.
doi: 10.1002/pds.5777.

Effects of the valsartan recall on heart failure patients: A nationwide analysis

Joshua W Devine  1 , Mina Tadrous  2   3 , Inmaculada Hernandez  4 , Nandita Mukhopadhyay  5 , Scott D Rothenberger  6 , Katherine Callaway Kim  6   7 , Walid F Gellad  6   8 , Katie J Suda  6   8
Affiliations

Effects of the valsartan recall on heart failure patients: A nationwide analysis

Joshua W Devine et al. Pharmacoepidemiol Drug Saf. 2024 Apr.

Abstract

Background: Valsartan is commonly used for cardiac conditions. In 2018, the Food and Drug Administration recalled generic valsartan due to the detection of impurities. Our objective was to determine if heart failure patients receiving valsartan at the recall date had a greater likelihood of unfavorable outcomes than patients using comparable antihypertensives.

Methods: We conducted a cohort study of Optum's de-identified Clinformatics® Datamart (July 2017-January 2019). Heart failure patients with commercial or Medicare Advantage insurance who received valsartan were compared to persons who received non-recalled angiotensin receptor blockers (ARBs) and angiotensin converting enzyme-inhibitors (ACE-Is) for 1 year prior and including the recall date. Outcomes included a composite for all-cause hospitalization, emergency department (ED), and urgent care (UC) use and a measure of cardiac events which included hospitalizations for acute myocardial infarction and hospitalizations/ED/UC visits for stroke/transient ischemic attack, heart failure or hypertension at 6-months post-recall. Cox proportional hazard models with propensity score weighting compared the risk of outcomes between groups.

Results: Of the 87 130 adherent patients, 15% were valsartan users and 85% were users of non-recalled ARBs/ACE-Is. Valsartan use was not associated with an increased risk of all-cause hospitalization/ED/UC use six-months post-recall (HR 1.00; 95% CI 0.96-1.03), compared with individuals taking non-recalled ARBs/ACE-Is. Similarly, cardiac events 6-months post-recall did not differ between individuals on valsartan and non-recalled ARBs/ACE-Is (HR 1.04; 95% CI 0.97-1.12).

Conclusions: The valsartan recall did not affect short-term outcomes of heart failure patients. However, the recall potentially disrupted the medication regimens of patients, possibly straining the healthcare system.

Keywords: drug recall; drug shortages; heart failure; valsartan.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. De Weerdt E, Simoens S, Casteels M, Huys I. Clinical, economic and policy implications of drug shortages in the European Union. Appl Health Econ Health Policy. 2017;15(4):441‐445. doi:10.1007/s40258‐016‐0264‐z
    1. Eggertson L. Continuing drug shortages affect north American patients. CMAJ. 2010;182(18):E811‐E812. doi:10.1503/cmaj.109‐3712
    1. Gray A, Manasse HR. Shortages of medicines: a complex global challenge. Bull World Health Organ. 2012;90(3):158‐158A. doi:10.2471/BLT.11.101303
    1. U.S. Food & Drug Administration. Drug Shortages: Root Causes and Potential Solutions. 2019 https://www.fda.gov/media/131130/download
    1. Reed BN, Fox ER, Konig M, et al. The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action. Am Heart J. 2016;175:130‐141. doi:10.1016/j.ahj.2016.02.004

Publication types

MeSH terms

Substances

LinkOut - more resources